significantly aided growth at 6 months more so in prepubertal than pubertal children. This was accompanied by significantly better lipid and glucose metabolism profiles without increases in graft rejection or loss.
Analysis 1.1. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 1 All-cause mortality.. .. Analysis 1.2. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 2 Total cardiovascular events. Analysis 1.3. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 3 Fatal cardiovascular.. .. Analysis 1.4. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 4 Non-fatal cardiovascular events. Analysis 1.5. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 5 Total coronary.. .. .. Analysis 1.6. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 6 Fatal coronary event.. .. Analysis 1.7. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 7 Non-fatal coronary event.. Analysis 1.8. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 8 Total stroke.. .. .. Analysis 1.9. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 9 Fatal stroke.. .. .. . Analysis 1.10. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 10 Non-fatal stroke.. .. Analysis 1.11. Comparison 1 Any lipid-lowering regimen vs control: all trials, Outcome 11 Revascularization (HMG Co A Group / Statins
We aimed to provide an overview of kidney allocation policies related to children and pediatric kidney transplantation (KTx) practices and rates in Europe, and to study factors associated with KTx rates. A survey was distributed among renal registry representatives in 38 European countries. Additional data were obtained from the ESPN/ERA-EDTA and ERA-EDTA registries. Thirty-two countries (84%) responded. The median incidence rate of pediatric KTx was 5.7 (range 0À13.5) per million children (pmc). A median proportion of 17% (interquartile range 2À29) of KTx was performed preemptively, while the median proportion of living donor KTx was 43% (interquartile range 10À52). The median percentage of children on renal replacement therapy (RRT) with a functioning graft was 62%. The level of pediatric prioritization was associated with a decreased waiting time for deceased donor KTx, an increased pediatric KTx rate, and a lower proportion of living donor KTx. The rates of pediatric KTx, distribution of donor source and time on waiting list vary considerably between European countries.The lack of harmonization in kidney allocation to children raises medical and ethical issues. Harmonization of pediatric allocation policies should be prioritized.
. There were also no diVerences in the incidence of rejection in the first year: eight episodes in 13 patients v five episodes in nine patients, respectively. Phosphate, alkaline phosphatase (ALP), parathyroid hormone (PTH), and fasting insulin concentrations rose during the first year of treatment, but not thereafter. In the second year of treatment, HV remained above baseline. Conclusion-Treatment with rhGH improves growth in prepubertal and pubertal children with renal transplants, with no significant change in GFR or the incidence of rejection. Phosphate, ALP, PTH, and insulin increased during the first year of treatment. (Arch Dis Child 1998;79:481-487)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.